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Undifferentiated nasopharyngeal carcinoma (NPC; WHO type III) is 100% associated with Epstein-Barr
virus (EBV) infection and the fourth most prevalent cancer in Indonesian males. Therapy failure is high, since
most patients come to the hospital at an advanced stage of disease. Screening for early-stage NPC is needed.
Here, a simple and economical two-step enzyme-linked immunosorbent assay (ELISA) system is proposed for
diagnosing NPC in high-risk populations, employing the peptide-based immunoglobulin A (IgA) EBNA1 plus
viral capsid antigen p18 ELISA as an initial screening test and the IgA early antigen (EA) ELISA using a
different set of EBV antigens as a confirmation test. A total of 151 NPC patients and 199 regional healthy EBV
carriers were used to evaluate the two-step ELISA approach. Routinely, EBV IgG immunoblotting is used as
a standard confirmation test. The sensitivity and specificity for diagnosing NPC by the two-step ELISA
approach increased from 85.4% to 96.7% and 90.1% to 98%, respectively, with positive predictive values and
negative predictive values increasing from 78.7 and 93.9% to 97.3 and 97.5%, respectively, relative to the
immunoblotting confirmation system. On discrepant samples, additional testing was done by EBV DNA load
quantification in blood. Results showed that 5/11 discrepant NPC samples with an elevated IgA EA ELISA also
had elevated an EBV DNA load in the circulation (range, 3,200 to 25,820 copies/ml). Therefore, the IgA EA
ELISA is proposed as a confirmation test in first-line NPC serological screening studies. This two-step EBV
ELISA system provides a standardized approach for NPC screening and may be used in combination with dried
blood sampling in future field studies for identification of early-stage NPC in high-risk regions.
Nasopharyngeal carcinoma (NPC) is a common cancer in
China and Southeast Asia and closely associated with Epstein-
Barr Virus (EBV) (26). In Indonesia, especially in the southern
part of central Java, undifferentiated carcinoma (WHO type
III) is the most common head and neck cancer and among the
five most prevalent cancers overall. Due to unspecific symp-
toms and the hidden localization of the primary tumor at the
early stage, more than 80% of the patients come to the hospital
at a late stage (III or IV), when they already have metastasis in
the cervical lymph node. Whereas late-stage disease has a poor
prognosis and requires combined chemo-radiotherapy, early-
stage NPC may reach complete remission by radiotherapy only
(17). Therefore, screening for early-stage NPC among the pop-
ulation is important and clinically relevant. For developing
countries, such an approach should be economical, employing
standardization methods suited for mass screening.
Patients with NPC have high-level broad-spectrum anti-
EBV antibodies, especially immunoglobulin A (IgA), com-
pared to regional healthy carriers and patients with other head
and neck diseases (13, 14). Our group recently demonstrated
that the molecular diversity underlying anti-EBV IgG and IgA
responses in NPC patients was different, requiring multiple
EBV antigens for complete serological coverage (7). Prior
studies in China and Taiwan have shown the feasibility of using
IgA serology for population screening (2, 15, 27). However, in
these studies laborious and poorly standardized cell-based se-
rological techniques were used. Nevertheless, these studies
revealed the appearance of serological abnormalities, i.e., pos-
itive EBV IgA responses 2 to 3 years prior to onset of NPC (2,
15), which clearly demonstrated the opportunity of using EBV
serology for early-stage detection of NPC. This particularly
applies for screening in high-risk groups, such as family mem-
bers of NPC patients and patients with suspicious head and
neck symptoms (18, 21).
For NPC serodiagnosis, cell-based indirect immunofluores-
cent assay (IFA) methods are still widely considered the gold
standard. IFA involves the separate analysis of antibody re-
sponses to viral capsid antigen (VCA), early antigen (EA), and
nuclear antigens (EBNA), each comprising multiple proteins
and requiring different cell lines for specific analysis (10, 12,
13). However, this method shows considerable variation
among laboratories and is time-consuming, subjective, and not
suitable for large-scale automatic handling. Enzyme-linked im-
munosorbent assay (ELISA) techniques are increasingly used
and have shown a better sensitivity and specificity compared to
IFA and are suitable for large-scale application (4, 10, 11, 16,
20, 21).
Recently, we developed an EBV IgA ELISA based on a
combination of VCA p18- and EBNA1-derived synthetic pep-
tides which is routinely used as an NPC diagnostic test in our
local hospital (Sardjito Hospital, Yogyakarta, Indonesia). This
EBV IgA ELISA combines the separate features of IgA VCA
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and IgA EBNA1, each of which has its value in NPC diagnosis.
The combination of these markers in a single assay provided
sensitivity and specificity of 85.4% and 90.1%, respectively (8).
The presence of NPC-related serological abnormalities can be
confirmed by immunoblotting to reveal the spectrum of anti-
body responses, which has diagnostic value by itself (5, 7, 16,
25). The combined EBV IgA ELISA and immunoblot assay
showed increased sensitivity and specificity and positive pre-
dictive value (PPV) and negative predictive value (NPV) of
more than 95% (7, 8). Because immunoblot studies revealed a
diagnostic value of multiple EBV proteins, in particular certain
EBV-EA markers, we recently developed a separate IgA EA
ELISA using native EA proteins (22). In addition to their role
in primary diagnosis, anti-EBV IgA responses, in particular the
IgA EA response, also have a distinct role for posttreatment
follow-up monitoring, as declining responses correlate with a
good prognosis and increasing responses are related to persis-
tence of relapsing tumor (6, 16, 24). The availability of two
distinct and biochemically well-defined EBV IgA ELISA sys-
tems addressing responses to different EBV antigens for NPC-
specific serology may add to further standardization. In this
study we evaluate the combination of these two tests for pri-
mary diagnosis of NPC in a high-incidence population in In-
donesia.
MATERIALS AND METHODS
Sera. Serum samples of NPC patients (n  151) and healthy donors (n  199)
were obtained from the archives of the Gadjah Mada University, Yogyakarta,
Indonesia. The NPC sera were taken on the first visit of patients. NPC staging
was done by ear, nose, and throat examination and computer tomography (CT)
scan and classified according to the 1997 Union International Cancer Control
criteria. The NPC cases were confirmed by biopsy, with paraffin sections stained
for EBV presence by standard Epstein Barr virus-encoded RNA–RNA in situ
hybridization using a Peptide-based nucleic acid kit (Dako, Glostrup, Denmark)
and by EBNA1 detection using monoclonal antibody OT1X (J. M. Middeldorp,
VUMC, Amsterdam, The Netherlands). Sera from normal healthy donors were
obtained from the local Red Cross blood bank.
Cell culture and cell extracts. The P3HR1-derived cell line HH514.c16 (pro-
vided by G. Miller, Yale University, New Haven, CT) was grown at 37°C in
flat-bottom or roller bottle culture, and cells were induced for expression of EA
by culturing the cells at 1.5  106 cells/ml for 3 days at 32°C in the presence of
3 mM sodium butyrate, 20 ng/ml 12-O-tetradecanoylphorbol-1-acetate, and 0.5
mM phosphonoacetic acid. Purified nuclei from EA- or VCA-induced cells were
prepared by Ficoll step gradient centrifugation exactly as described before (19).
All cell culture chemicals were from Sigma, St. Louis, MO.
EBV antigens and EBV IgA ELISA. The EA antigen used in this study was
produced by 0.3 M salt extractions from purified EA nuclei as described else-
where (22). Synthetic peptides for the EBNA1 plus VCA p18 ELISA
([EBNA1VCA p18] ELISA) have been described before (7). Both ELISAs
have been validated for NPC diagnosis in large panels of biopsy-confirmed NPC
cases and regional controls, including blood bank donors and patients with
non-NPC malignant and nonmalignant diseases presenting in the head and neck.
Standard ELISA plates (Greiner, Frickenhausen, Germany) were coated at
4°C overnight with 150 l of a mixture of EBV VCA p18 and EBNA1 peptides
or EA nuclear extract at 1 g/ml in 50 mM sodium carbonate buffer, pH 9.6.
Nonspecific binding was blocked for 1 h with phosphate-buffered saline
(PBS)–3% bovine serum albumin at 37°C. Serum and conjugate incubations were
for 1 h at 37°C followed by four washes with PBSt (PBS–0.1% [vol/vol] Triton-X,
1% bovine serum albumin). Human sera were diluted 1:100 in dilution buffer
(PBSt, with an additional 1% normal rabbit serum for the IgA EA ELISA).
Horseradish peroxidase-labeled rabbit anti-human IgA (Dako, Copenhagen,
Denmark) was used at 1:4,000 in dilution buffer (with an additional 1% normal
rabbit serum for the IgA EA ELISA), respectively. Horseradish peroxidase
activity was detected by 3,3,5,5-tetramethylbenzidine (bioMerieux, Boxtel, The
Netherlands) and stopped by adding 1 M H2SO4. The optical density at 450 nm
(OD450) was determined and cutoff values (CoVs) were determined by receiver
operating characteristic (ROC) analysis (8, 22).
Immunoblot assays. In-house immunoblot assays using recombinant proteins
or natural EBV antigen prepared from superinducible HH514 cells were done as
described previously (7, 19, 22). Details and interpretation of immunoblot pat-
terns have been described before (5, 7, 16, 25). For some experiments we used
purified in-house recombinant proteins as described elsewhere (22).
Unfractionated whole-blood samples and EBV DNA load quantification by
quantitative Light Cycler-based real-time PCR. Unfractionated EDTA-antico-
agulated whole-blood samples were obtained from NPC patients at the time of
diagnosis and before any therapeutic intervention during their visit to Sardjito
Hospital, Yogyakarta, Indonesia. Nucleic acid isolation and in-house Light
Cycler-based real-time PCR procedures for EBV DNA load quantification, cre-
ating a 99-bp amplimer from a conserved region of the EBNA1-encoding
BKRF1 gene, have been described elsewhere (23).
Data analysis. All statistical analyses were done with the GraphPad Prism
version 4.00 program (NJ). Cutoff values were determined by the ROC
analysis based on the OD value of sera from 254 healthy donors and 151 NPC
patients (3).
RESULTS
Distribution of study population. NPC patients were re-
cruited prospectively during 2001 to 2003 at the Sardjito Hos-
pital, Yogyakarta, Indonesia, at first visit prior to any thera-
peutic treatment. The male/female ratio was 2.3 (104/45). The
age distribution ranged between 18 and 80 years with the
majority between 31 and 60 years (mean, 46.8 years). Most
patients (48%) were at stage IVB, and only 17/151 (11.3%)
were at an early stage (I, IIA, or IIB) (Fig. 1).
Initial diagnosis using either IgA [EBNA1VCA p18] or
IgA EA ELISA. Analysis in healthy EBV carriers (n 199) and
NPC patients (n  151) of serum IgA reactivity to
[EBNA1VCA p18] and EA using ELISA showed mean
OD450 values of 0.19 and 0.16 for EBV carriers, whereas NPC
patients yielded values of 1.48 and 1.39, respectively. The range
of individual OD450 values for each ELISA are shown in Fig. 2.
All healthy donors were EBV IgG seropositive, confirming
their EBV carrier status (data not shown). The optimal CoV
was defined by ROC analysis at 0.35 and 0.22 for
[EBNA1VCA p18] and EA, respectively (3). This yielded
sensitivity and specificity values of 85.4% and 90.1% for the
IgA [EBNA1VCA p18] and 85.7% and 94% for the IgA EA
ELISA.
To illustrate that both ELISA systems detected different
EBV IgA responses, the individual OD450 values in the IgA
[VCA p18EBNA1] ELISA and IgA EA ELISA for NPC
cases at different stages were interconnected, revealing that
although some sera showed similar reactivities in both ELISAs,
generally a different level of response was detected (Fig. 3).
Overall, 21/199 (10.6%) of healthy EBV IgG-seropositive
blood donors were above the CoV in the peptide-based EBV
IgA [EBNA1VCA p18] ELISA, usually with rather low
OD450 values (Fig. 2), and were initially classified as false
positives. On the other hand, 15/151 (10%) confirmed NPC
cases were at or below CoV in the EBV-IgA ELISA and were
classified as false negatives in the initial screening test.
To further analyze false-positive and false-negative results,
we performed EBV immunoblotting for IgG diversity. Nine of
21 false-positive healthy carriers had OD450 ELISA values in
the gray area (i.e., within 0.20 of the CoV). All were tested for
IgG diversity and showed a normal pattern, with six donors
(pmi-3, pmi-67, pmi-88, pmi-108, pmi-154, and pmi-185) not
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revealing IgG EBV reactivity, in agreement with previous find-
ings by Fachiroh et al. (7) (Table 1). Fifteen false-negative
NPC sera were tested for IgG diversity by immunoblotting, and
10 of them gave an IgG high-diversity pattern (3/4), re-
flecting presence of NPC.
In our current routine NPC diagnosis at Sardjito hospital,
because of the known level of false positivity, a positive IgA
[EBNA1VCA p18] reactivity is paralleled by immunoblot
analysis for detection of abnormal IgG diversity, which is an
effective but laborious method. Therefore, we here evaluated
replacement of the immunoblotting with an IgA EA ELISA as
a routine confirmation test.
IgA EA as the confirmation test of IgA [EBNA1VCA p18].
Fifteen false-negative and 21 false-positive samples in the EBV
IgA peptide-based screening ELISA (as defined above) were
analyzed by immunoblotting to evaluate the IgG diversity to
EBV proteins. The result revealed that 10/15 false negatives
gave an IgG diversity pattern supportive of NPC, and all of the
false-positive samples revealed a low or normal diversity pat-
tern, supportive of uncomplicated EBV carriership. By IgA EA
ELISA, 10/15 false negatives were identified as real NPC based
on IgA EA values above the cutoff, and 8 of them were also
confirmed by IgG immunoblotting. The IgA EA ELISA also
revealed 19 of 22 false positives were confirmed as normal,
based on IgA EA values below the cutoff (Tables 1 and 2).
Therefore, the IgA EA ELISA can reliably replace immuno-
blotting as a confirmation assay. By using the IgA EA ELISA
as the confirmation test, as shown in Table 3 the sensitivity and
specificity of the two-step EBV IgA ELISA versus the one-step
peptide-based ELISA for identification of true NPC cases in-
FIG. 1. Distribution of disease stage at presentation of 151 NPC patients, showing 11.3% were at an early stage (I, IIA, or IIB) and 88.7% were
at a late stage (IIIA to IVB), with most of them (48%) being at stage IVB with distant metastasis.
FIG. 2. Distribution frequency of EBV IgA ELISA values in the Indonesia panel for combination [EBNA1VCA p18] antigen (A) and EA
extract (A). Shown are the mean OD450 values and 25th and 75th percentiles of OD450 values for IgA reactivity in both ELISAs, using Indonesian
serum panels consisting of healthy blood donors (n  199) and NPC patients (n  151). The cutoff values of both tests were 0.35 for IgA
[EBNA1VCA p18] and 0.22 for IgA EA. IgA reactivities to the [EBNA1VCA p18] and EA ELISAs showed mean OD450 values of 0.19 and
0.16 for healthy EBV carriers (HC), and NPC patients had mean OD450 values of 1.48 and 1.39, respectively. These differences were highly
significant (P  0.0001).
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creased from 85.4% to 96.7% and 90.1% to 98%, respectively,
and PPV and NPV values increased from 78.7 and 93.9% to
97.3 and 97.5%, respectively.
Confirmation of discrepant samples by EBV DNA load. Six
of 10 false negatives identified as possible NPC by IgA EA
ELISA and from whom a whole-blood sample was available
were tested for EBV DNA load in whole blood using the 99-bp
EBNA1-based Light Cycler PCR as described before (23). Five
of six had EBV copy numbers above the CoV (CoV, 2,000
copies/ml), ranging from 3,200 to 25,820 copies/ml (mean,
16,364 copies/ml), conforming their aberrant EBV activity and
supportive of an NPC diagnosis.
DISCUSSION
In countries with a high NPC incidence, such as Indonesia,
screening for early-stage disease is very important, since most
patients currently come to the hospital at stage III or IV, with
the consequences of therapy failure and a low survival rate
posing considerable health care problems. Detection of EBV-
FIG. 3. IgA [EBNA1VCA p18] and IgA EA ELISA values for NPC patients at different stages of the disease. For each case, lines
interconnect OD450 values in both ELISA systems. This reveals a generally different response level in either test, indicating that both ELISA
systems detect distinct EBV IgA reactivities and may function for complementary serological testing.
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related serological abnormalities, such as elevated EBV IgA
levels, may provide a timely diagnosis of protracted early-stage
NPC, as revealed in recent studies (2, 15). The availability of
affordable yet accurate serological tests, which can be auto-
mated for large-scale applications, will be of benefit to cancer
screening programs in developing countries. The IgA ELISA
using defined and distinct EBV antigen may fulfill the criteria
for such a screening approach, in particular when combined
with simple sampling, such as dried blood collection, as shown
by us recently (9). In that study, sera from well-defined groups
of NPC patients and regional healthy individuals were used to
evaluate the performance of a two-step ELISA system for
detection and confirmation of NPC. The overall results showed
that the two-step algorithm, using the peptide-based IgA
[EBNA1VCA p18] as the initial screening test and protein-
based IgA EA as the confirmatory test, can provide highly
sensitive and specific noninvasive detection of NPC.
The EBV IgA ELISA based on defined EBNA1 and VCA
p18 synthetic peptide antigens combined in a single well fulfills
the criteria for a well-standardized and cheap screening test.
Peptides may be suitable replacements for natural or recom-
binant proteins as stable, reproducible, and cheap sources of
antigen for an ELISA. Our data have shown that the peptide-
based EBV IgA ELISA not only discriminates NPC patients
from healthy EBV carriers (Fig. 2) but also from non-NPC
tumor patients in a region with a high NPC prevalence (8).
Importantly, the newly developed IgA EA ELISA addresses
IgA responses to a distinct set of native EBV nuclear EA
proteins as confirmed in this study (Fig. 3). Therefore, the
combination of both IgA ELISAs provides additive indepen-
dent serological information, contributing to improved diag-
nosis.
The combination of different technologies, like serology and
EBV DNA load testing, was previously advised for diagnosis of
NPC (20). EBV DNA load and serology are independent pa-
rameters, which means that they are not quantitatively related
to each other. Therefore, the combination of these parameters
will increase the diagnostic sensitivity (1, 23). Table 2 shows
that NPC cases with low values for both EBV IgA ELISAs also
have whole-blood EBV DNA loads below the CoV, and three
of five with high EBV IgA responses also gave positive EBV
DNA loads. This indicates that EBV DNA load may be used to
confirm serology. However, EBV DNA load is positive in only
some NPC patients and frequently is found at low levels. Fur-
thermore, PCR techniques are cumbersome and require ultra-
clean lab facilities, which are difficult to realize and relatively
expensive in developing countries.
In our hospital the EBV immunoblot assay, revealing the
broad range (diversity) of IgG responses to EBV lytic proteins,
is routinely used as a confirmation test, providing increased
sensitivity and specificity and PPV and NPV values of greater
than 95% for NPC diagnosis (8). However, immunoblot strip
preparation and analysis are laborious. The immunoblot stud-
ies revealed the contribution of certain EA antigens as impor-
tant markers of NPC-specific serology. Therefore, an indepen-
TABLE 1. IgA EA ELISA values and IgG immunoblot scores for
sera of healthy EBV carriers with low positive results for
the IgA EBNA1VCA p18 ELISA
Patient
code
IgA ELISA (OD) fora:
IgG immunoblot
diversity scorebEBNA1VCA p18
(CoV, 0.354) EA (CoV, 0.2162)
pmi-3 0.449* 0.254** 	
pmi-9 0.541 0.171 1
pmi-12 0.830 0.199 2
pmi-17 0.490* 0.158 1
pmi-26 0.527 0.131 1
pmi-29 0.441* 0.109 1
pmi-30 0.374* 0.128 1
pmi-43 0.463* 0.150 1
pmi-54 1.296 0.114 1
pmi-67 0.364* 0.135 	
pmi-88 0.684 0.247** 	
pmi-91 1.462 0.143 1
pmi-92 1.014 0.105 1
pmi-95 0.532 0.210 1
pmi-108 1.813 0.138 	
pmi-152 0.492* 0.044 1
pmi-154 0.613 0.100 	
pmi-173 0.395* 0.067 1
pmi-185 1.977 0.132 	
pmi-194 0.418* 0.266** 1
pmi-204 0.904 0.183 1
a *, IgA EBNA1VCA p18 ELISA value in the gray area; **, IgA EA value
above the cutoff.
b IgG diversity score: 	, negative; 1, normal; 2, normal reactive; 3 and
4, NPC pattern.
TABLE 2. EBV IgA ELISA value, IgG immunoblot
result, and EBV DNA load of NPC cases with
IgA-EBNA1VCAp18 below cutoff
Sample
code
IgA ELISA (OD) for:
Immunoblot
diversity
scorea
EBV DNA
load/ml
(CoV, 2,000)
EBNA1
VCA p18
(CoV, 0.354)
EA
(CoV, 0.216)
01-2 0.253 0.530 3 NAb
01-3 0.274 3.407 4 NA
01-20 0.071 0.219 1 NA
01-46 0.213 0.167 1 200
01-56 0.201 0.155 3 0
02-11 0.338 1.118 4 23,400
02-37 0.081 1.182 4 7,600
02-48 0.115 0.217 3 3,200
02-79 0.288 0.236 2 NA
02-83 0.114 0.159 2 1,380
03-9 0.007 0.131 1 400
03-10 0.298 0.256 4 25,820
03-23 0.348 0.237 4 0
03-24 0.301 0.196 4 400
03-51 0.341 0.445 4 21,800
a IgG diversity score: 	, negative; 1, normal; 2, normal reactive; 3 and
4, NPC pattern.
b NA, not available.
TABLE 3. Diagnostic performance of EBV IgA ELISA for the
Indonesia panel consisting of sera from 199 healthy
EBV carriers and 151 NPC patients
Test Sensitivity(%)
Specificity
(%) PPV (%) NPV (%)
IgA EBNA1VCA p18 85.4 90.1 78.7 93.9
IgA EA 85.7 94.0 79.4 94.9
IgA EBNA1VCA p18
combined with IgA EA
96.7 98 97.3 97.5
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dent serological test based on EA might be useful not only for
confirmation but also for posttreatment prognostic monitoring
in NPC (16, 22). Based on this study the IgA EA ELISA is
proposed for the confirmation assay.
The two-step serological screening approach may permit
identification of early-stage NPC cases by screening at-risk
populations and thus contribute to improve early treatment
and outcome of the disease. To confirm possible early-stage
NPC in at-risk patients with positive EBV IgA results, a non-
invasive nasopharyngeal brushing may be collected and exam-
ined for EBV DNA and RNA as described recently (24).
Positive results directly reflect carcinogenic activity, in partic-
ular with detection of the carcinoma-specific EBV BARF1
mRNA. In a preliminary ongoing study at Sardjito Hospital,
we are now screening random patients with chronic head and
neck problems who are unresponsive to antibiotic treatment,
and we have identified 2 true early-stage NPC cases among 30
patients analyzed using this two-step screening approach. If
our work can confirm the early-stage diagnosis in larger pop-
ulations, further expansion to family members of NPC patients
and regional field hospitals is indicated.
Conclusions. The two-step EBV IgA ELISA approach pro-
vides a reliable diagnostic format for NPC diagnosis and is
proposed for screening of NPC in populations with high EBV
prevalence, such as in Indonesia and other parts of Southeast
Asia.
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